Ovid Therapeutics Inc. (OVID)
OVID Stock Price Chart
Explore Ovid Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze OVID price movements and trends.
OVID Company Profile
Discover essential business fundamentals and corporate details for Ovid Therapeutics Inc. (OVID) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 2017
Employees
23.00
Website
https://www.ovidrx.comCEO
Margaret Alexander
Description
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
OVID Financial Timeline
Browse a chronological timeline of Ovid Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.10, while revenue estimate is $35.00k.
Earnings released on 12 May 2026
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 18 Mar 2026
EPS came in at $0.06 surpassing the estimated -$0.10 by +160.00%, while revenue for the quarter reached $718.00k , beating expectations by +817.57%.
Earnings released on 12 Nov 2025
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $132.00k , beating expectations by +110.86%.
Earnings released on 13 Aug 2025
EPS came in at -$0.06 surpassing the estimated -$0.16 by +62.50%, while revenue for the quarter reached $6.27m , beating expectations by +10.13k%.
Earnings released on 13 May 2025
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $130.00k , beating expectations by +205.88%.
Earnings released on 11 Mar 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $76.00k , missing expectations by -24.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%, while revenue for the quarter reached $173.00k , missing expectations by -7.73%.
Earnings released on 13 Aug 2024
EPS came in at $0.12 surpassing the estimated -$0.22 by +154.55%, while revenue for the quarter reached $169.00k , beating expectations by +141.43%.
Earnings released on 14 May 2024
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $148.00k , beating expectations by +146.67%.
Earnings released on 8 Mar 2024
EPS came in at -$0.22 falling short of the estimated -$0.17 by -29.41%, while revenue for the quarter reached $141.56k , beating expectations by +135.94%.
Earnings released on 3 Nov 2023
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $108.97k , beating expectations by +81.62%.
Earnings released on 4 Aug 2023
EPS came in at -$0.18 surpassing the estimated -$0.21 by +14.29%, while revenue for the quarter reached $75.00k , beating expectations by +50.00%.
Earnings released on 5 May 2023
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%, while revenue for the quarter reached $66.00k , beating expectations by +230.00%.
Earnings released on 13 Mar 2023
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%, while revenue for the quarter reached $46.28k .
Earnings released on 8 Nov 2022
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $11.10k .
Earnings released on 9 Aug 2022
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 10 May 2022
EPS came in at -$0.23 falling short of the estimated $1.17 by -119.66%, while revenue for the quarter reached $1.45m , beating expectations by +10.53%.
Earnings released on 15 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.17 by -123.53%, while revenue for the quarter reached -$416.35m .
Earnings released on 10 Nov 2021
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%.
Earnings released on 16 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.15 by -53.33%.
OVID Stock Performance
Access detailed OVID performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
